Cystic fibrosis

ReCode Therapeutics to Expand Next-Generation Delivery Platform and Diversify Genetic Medicines Pipeline with Oversubscribed Series B Financing Totaling $200M

Retrieved on: 
Wednesday, June 29, 2022
Science, Other Science, Research, Pharmaceutical, Finance, Health, Professional Services, Genetics, Cell, CF, SORT, Patient, RNA transfection, Moses Austin, Liver, Protein, Nature, LNP, Precision medicine, COVID, Health, American Thoracic Society, CNS, Blood, Central nervous system, Spleen, Disease, Industry, Recode, ATS, Bayer, MBA, PCD, Therapy, Sirna, Technology, IND, RNA, COVID-19 vaccine, University, Lung, DNA, Cystic fibrosis, Solution, Time, International Conference on Emerging Infectious Diseases, Lists of diseases, IV, Conference, Pharmaceutical industry, Vaccine, Matrix, Finance Secretary (India)

With the additional $120M in new financing, the company has secured a total of $200M in Series B funding.

Key Points: 
  • With the additional $120M in new financing, the company has secured a total of $200M in Series B funding.
  • I am delighted to join ReCodes Board during this important growth trajectory for the company and am eager to work with the leadership team to expand ReCodes next generation genetic medicines delivery platform and diversify its pipeline.
  • ReCode is differentiated by its first-in-class modular genetic medicines delivery platform.
  • ReCode Therapeutics is a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics.

Santhera Updates on Ongoing NDA Submission for Vamorolone

Retrieved on: 
Wednesday, June 29, 2022
Review, Vitamin D deficiency, FDA, Life Science Alliance, Dissociative, Duchenne muscular dystrophy, Vamorolone, Patient, European Medicines Agency, Time, LHON, MAA, Orphan drug, DMD, Company, UK, Vomiting, CMO, PIM, EMA, JAMA Network Open, Food, Leber's hereditary optic neuropathy, Communication, Microdeletion syndrome, Cystic fibrosis, Agency, Safety, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NDA, Pharmaceutical industry, Vaccine

Santhera commenced the NDA filing as a rolling submission in March 2022 following a successful pre-NDA meeting with the FDA.

Key Points: 
  • Santhera commenced the NDA filing as a rolling submission in March 2022 following a successful pre-NDA meeting with the FDA.
  • In its conclusions from this meeting, the FDA considered the proposed clinical efficacy and safety data sufficient to support an NDA filing of vamorolone for the treatment of DMD.
  • Therefore, Santhera will discuss with the Agency the status and updated timelines for completing the NDA filing by Q4-2022.
  • The Company plans to complete the rolling submission of its filing for approval for vamorolone with the U.S. FDA.

Monaghan Medical and Children’s Hospital Association join forces to improve patient outcomes

Retrieved on: 
Tuesday, June 28, 2022
Patient, Cystic fibrosis, COPD, Hospital, American Animal Hospital Association, GLOBE, COVID-19, CHA, Industry, Children's Hospital Association, Pediatrics, Partnership, Marketing, Technology, Health, Quality of life, Gold, Degenerative disease, Child, Aerosol, Research, Asthma, Oscillation, Respiratory therapist, Pharmaceutical industry, Medicine

PLATTSBURGH, N.Y., June 28, 2022 (GLOBE NEWSWIRE) -- Monaghan Medical Corporation (Monaghan) and Childrens Hospital Association (CHA) today announce their agreement to a three-year contract creating a partnership between two industry leaders.

Key Points: 
  • PLATTSBURGH, N.Y., June 28, 2022 (GLOBE NEWSWIRE) -- Monaghan Medical Corporation (Monaghan) and Childrens Hospital Association (CHA) today announce their agreement to a three-year contract creating a partnership between two industry leaders.
  • Signing both categories agreements together at once recognizes Monaghans reputation for both industry leading technology and proven clinical outcomes.
  • They recognize that cost savings fully materialize when staff efficiencies, inventory consolidation, and patient outcomes all improve.
  • The Children's Hospital Association brings together the clinical and administrative leaders of children's hospitals to create meaningful change in children's health care and child health.

Santhera Nominates Thomas Meier, PhD, to Succeed Elmar Schnee as Chairman of the Board

Retrieved on: 
Monday, June 27, 2022
Financial compensation, Board of directors, Patient, Vamorolone, CEO, Annual, LHON, DMD, Company, CEST, Proxy, Leber's hereditary optic neuropathy, Communication, Doctor of Philosophy, Cystic fibrosis, Annual general meeting, Board, Leadership, Professional Football Compensation Committee, Management, Pharmaceutical industry, Director

Pratteln, Switzerland, June 27, 2022 -- Santhera Pharmaceuticals (SIX: SANN) announces that Chairman of the Board Elmar Schnee will not stand for re-election at the upcoming Annual General Meeting on June 30, 2022. The Board of Directors has unanimously nominated Thomas Meier, PhD, for election as Chairman of the Board and as member of the Compensation Committee.

Key Points: 
  • The Board of Directors has unanimously nominated Thomas Meier, PhD, for election as Chairman of the Board and as member of the Compensation Committee.
  • Elmar Schnee, Chairman of the Board and member of the Compensation Committee of Santhera since 2017, will not stand for re-election and will step down from Santhera's Board of Directors as of June30, 2022.
  • The Board of Directors expresses its sincerest gratitude to Mr. Schnee for his valued leadership over the past, challenging years.
  • The Board of Directors of Santhera has unanimously nominated Thomas Meier, PhD, for election as Chairman of the Board and as member of the Compensation Committee.

Transamerica Enhances Coverage Within Its Workplace Supplemental Health Benefits Suite

Retrieved on: 
Monday, June 27, 2022
Insurance, Down syndrome, Disability, Acupuncture, Senior, Workforce, Jean-Louis Vincent, History, Mental, Aegon, Policy, Cerebral palsy, Threshold limit value, Retirement, Investment, Cardiovascular disease, Accident insurance, Employee benefits, Health, Cystic fibrosis, Solution, Time, Transamerica Corporation, Neurodevelopmental disorder, Observation, Federal Employees' Group Life Insurance Act, Health insurance, Life insurance, Transamerica

BALTIMORE, June 27, 2022 /PRNewswire/ -- Transamerica announced today the expansion of its workplace benefits offerings with refreshed supplemental Transamerica Accident InsuranceSM and Transamerica Critical Illness InsuranceSM policies available for employers to offer employees.

Key Points: 
  • BALTIMORE, June 27, 2022 /PRNewswire/ -- Transamerica announced today the expansion of its workplace benefits offerings with refreshed supplemental Transamerica Accident InsuranceSM and Transamerica Critical Illness InsuranceSM policies available for employers to offer employees.
  • New benefits include:
    An organized sports benefit rider that pays an additional percentage of total benefits, making this policy ideal for active families.
  • Mental health benefits that allow up to five annual mental health visits with a psychiatrist or psychologist at up to $150 per visit.
  • "Transamerica recognizes the need for protection that goes beyond common conditions," said John Stanley, Senior Managing Director of Employee Benefits at Transamerica.

Berkshire Hathaway HomeServices Expands Global Presence in Italy

Retrieved on: 
Monday, June 27, 2022
Construction & Property, Residential Building & Real Estate, Berkshire, CEO, USD, Capital, Attention, Marriott International, HomeServices of America, Bel paese (phrase), Growth, Industry, Longevity, Association, Trust, ROMA, Prestige (magazine), General counsel, Organization, Berkshire Hathaway, Program, Cystic fibrosis, Social media, Real estate

Berkshire Hathaway HomeServices , a global residential real estate brokerage franchise network, is pleased to announce its further expansion in Rome, Italy.

Key Points: 
  • Berkshire Hathaway HomeServices , a global residential real estate brokerage franchise network, is pleased to announce its further expansion in Rome, Italy.
  • By joining the network, Berkshire Hathaway HomeServices ROMA IMMOBILIARE agents gain access to Berkshire Hathaway HomeServices active referral and relocation networks, and its FOREVER Cloud technology suite, a powerful source for lead generation, marketing support, social media, video production/distribution and more.
  • Christy Budnick, CEO of Berkshire Hathaway HomeServices, commented, "Italy and Rome need no presentation worldwide.
  • In 2021, the Berkshire Hathaway HomeServices global network represented more than $179.9 billion (USD) in real estate sales volume.

BiomX Announces Dosing of the First Two Patients in Phase 1b/2a Study of BX004 for Treatment of Chronic Respiratory Infections in Patients with Cystic Fibrosis

Retrieved on: 
Monday, June 27, 2022
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, FDA, Clinical Trials, Department, CF, Patient, Conditional sentence, Valencia CF Foundation, Pseudomonas aeruginosa, Therapy, Phage therapy, U.S. Securities and Exchange Commission, Forward-looking statement, Mortality, Part, Pharmacokinetics, Cystic Fibrosis Foundation, Food, NYSE, FEV1, Pediatrics, Cystic fibrosis, SEC, Private Securities Litigation Reform Act, Safety, Disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Security (finance), Pharmaceutical industry

We are pleased to reach this important clinical milestone in our cystic fibrosis program, said Jonathan Solomon, Chief Executive Officer of BiomX.

Key Points: 
  • We are pleased to reach this important clinical milestone in our cystic fibrosis program, said Jonathan Solomon, Chief Executive Officer of BiomX.
  • Despite the significant advancements made in the treatment of cystic fibrosis, P. aeruginosa remains a leading cause of patients' morbidity and mortality.
  • BiomX is developing BX004 for the treatment of CF patients with chronic respiratory infections caused by Pseudomonas aeruginosa, a main contributor to morbidity and mortality in patients with CF.
  • In September 2021, BX004 was cleared by the U.S. Food and Drug Administration to initiate a Phase 1b/2a study in CF patients with chronic respiratory infections caused by Pseudomonas aeruginosa.

Claire's Place Foundation Hits the Seas for Cystic Fibrosis

Retrieved on: 
Friday, June 24, 2022
CF, Courage, Travel, Friends, Face, Awareness, Cystic fibrosis, Clair, Toy, Piper

LOS ANGELES, June 24, 2022 /PRNewswire-PRWeb/ -- Claire's Place Foundation, a non-profit organization providing support to children and families affected by cystic fibrosis (CF), is pleased to announce that they have a relay team competing in The Crossing for Cystic Fibrosis, a long-distance paddle challenge to help raise awareness and funding for CF.

Key Points: 
  • LOS ANGELES, June 24, 2022 /PRNewswire-PRWeb/ -- Claire's Place Foundation , a non-profit organization providing support to children and families affected by cystic fibrosis (CF), is pleased to announce that they have a relay team competing in The Crossing for Cystic Fibrosis , a long-distance paddle challenge to help raise awareness and funding for CF.
  • "It is a dream come true to have Claire's Place Foundation travel all the way from California to participate in this year's Crossing," said Founder of Piper's Angel's Foundation Travis Suit.
  • "Every fall and then getting back up on our boards has led to this day," said Claire's Place Foundation Executive Director Melissa Yeager.
  • We continue to carry on my daughter Claire's legacy of supporting the CF village through Claire's Place and incredible fundraisers such as The Crossing for CF.

Global Direct-to-Consumer (DTC) Genetic Testing Market Trajectory & Analytics, 2020-2022 & 2026 - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 23, 2022
Biotechnology, Genetics, Health, CAGR, COVID-19, Science, Gene, Growth, Ancestor, 23andMe, Lists of diseases, Conditional sentence, Cancer, Health, DTC, Adoption, Alzheimer's disease, Genetic, Medicine, Direct, Genetic testing, Awareness, Degenerative disease, Cystic fibrosis, Prevalence, Diabetes, Risk, Security (finance), Pharmaceutical industry, Vaccine, Pet

The "Direct-to-Consumer (DTC) Genetic Testing - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Direct-to-Consumer (DTC) Genetic Testing - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Public awareness regarding the availability of DTC genetic testing in developing as well as developed countries is continually rising.
  • Leading market players like Ancestry and 23andMe are focusing on offering high-quality DTC genetic testing solutions that ensure accurate and effective test results.
  • This segment currently accounts for a 21% share of the global Direct-to-Consumer (DTC) Genetic Testing market.

Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, June 22, 2022
Health, Infectious Diseases, Genetics, Research, Science, Pharmaceutical, Biotechnology, Messenger RNA, RNA, Patent, Therapy, COVID-19, Risk, Safety, Annual report, III, Janssen Pharmaceuticals, Vaccine, Director, Liver, Cystic fibrosis, Cystic Fibrosis Foundation, Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., Company, OTC, Takeda Pharmaceutical Company, LinkedIn, Glycogen storage disease type III, MicroRNA, Private Securities Litigation Reform Act, Hepatitis B virus, Financial compensation, DNA, Fatty liver disease, ARCT, Severe acute respiratory syndrome coronavirus 2, Gene editing, Intention, SEC, CureVac, Nasdaq, NASH, Twitter, Infection, Employment, Duke–NUS Medical School, Johnson & Johnson, RNA transfection, Arcturus

The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individuals employment compensation and were granted as an inducement material to his or her acceptance of employment with the Company.

Key Points: 
  • The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individuals employment compensation and were granted as an inducement material to his or her acceptance of employment with the Company.
  • The options have an exercise price equal to $12.26 per share, the closing price of the Companys common stock as reported by Nasdaq on June 16, 2022.
  • Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.
  • Arcturus technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China and other countries).